Clinical trial shows GLP-1s could be effective in children as young as 6. Should kids be using them?

Some doctors warn the long-term effects among kids are unknown.

New research shows a common weight loss medication may be effective in treating obesity in children as young as 6 years old.

Novo Nordisk shared results from a phase 3 clinical trial at an obesity medicine conference this week showing that its drug, Wegovy, reduced Body Mass Index by 10% or more among most children with obesity ages 6 through 11.

After 68 weeks, almost 40% of children taking semaglutide -- the active ingredient in Wegovy -- no longer had obesity. By comparison, nearly all the patients taking the placebo still had obesity after that period.

For children and adolescents ages 2 to 19, is traditionally defined as having a body mass index of 30 or higher.

Wegovy is currently approved by the Food and Drug Administration for children as young as 12 years old, but Novo Nordisk says it plans to file with the agency to lower the age.

The World Health Organization currently recommends against children under 10 years old receiving pharmacological weight-loss treatments and to instead focus on diet and exercise.

Physicians agree that obesity is a public and personal health concern that needs to be addressed; the Centers for Disease Control and Prevention says approximately one in five U.S. children and adolescents have obesity. However, there is mixed reaction among doctors regarding how widely GLP-1s should be used in younger children.

Boxes of weight-loss medication Wegovy are seen on a counter at a pharmacy in Chicago, April 24, 2024.
Scott Olson/Getty Images

Dr. Mary Pat Gallagher, director of the division of pediatric endocrinology and diabetes at Hassenfeld Children's Hospital at NYU Langone, who was not involved in the trial, referred to the findings as "a remarkable result."

Some doctors say that addressing obesity in young children by prescribing these medications can help prevent kids from developing severe obesity or related conditions, including fatty liver disease and sleep apnea.

Gallagher told ABC News some children already have those conditions and using GLP-1s could be a more effective treatment for obesity potentially reducing having to take several medications for these complications in the future.

"Instead of taking a blood pressure medication and some drug to treat fat in your liver or wearing a CPAP or a BiPAP at night for your obstructive sleep apnea, by treating obesity, you could be treating all of those with just one medication," Gallagher said.

Dr. Jade Cobern, board certified in pediatrics and preventive medicine, who was also not involved in the trial, said it's not surprising that GLP-1s are effective in a younger population, but there are some things to consider, such as side effects.

The Novo Nordisk study found there were no new major safety concerns, but gastrointestinal side effects were more common in the semaglutide group. Vomiting occurred in 70% of the participants in the semaglutide group compared to 29% of those in the placebo group, Cobern said.

Additionally, diarrhea occurred in 62% of the semaglutide group versus 35% of the placebo group and nausea in 58% and 24%, respectively, she added.

"When we talk about 70% of the kids in the semaglutide group in the study who experience vomiting, what that looks like for a 6-year-old, and the degree of how that can impact a 6-year-old is very different than how that might impact a 19-year-old or a 30-year-old," Cobern told ABC News. "How does that vomiting impact their ability to go about their day, their ability to stay in school, their ability to learn throughout the school day? These are really important questions that we are going to have to watch very closely."

There was also a difference in linear growth -- meaning the increase in length or height -- among children in the semaglutide group compared to the placebo group.

The trial found children on semaglutide grew about 1.3 inches less than those who did not take the drug. 

Cobern said more follow-ups are needed to understand how these drugs could impact a child's growth and body composition, both of which are important as children age.

The logo of pharmaceutical company Novo is displayed in front of its offices in Bagsvaerd, Denmark, November 3, 2026.
Tom Little/Reuters

Gallagher said when considering the benefits compared to the risks, the "theoretical possibility that someone might lose half an inch of height" would not prevent her from prescribing a GLP-1 to a child with obesity who has obstructive sleep apnea or high blood pressure, for example.

"I definitely don't want the message to be that we shouldn't use these medications [until] we have more information," Gallagher said. "I think we have a real problem with childhood obesity. It is a chronic illness and we do need to do something about it."

Cobern agreed that the medication is a potential tool for some children with severe obesity when diet and lifestyle interventions are insufficient, just not as a first-line or standalone approach.

"We do hear from obesity medicine doctors that they hit a wall in some of these younger age groups, and so they have wanted more tools in the toolbox, which this potentially could be," she said. "But again -- a tool -- [and] not the only tool and not the only focus."

Sponsored Content by Taboola